lm11a-31 and Cognition-Disorders

Topics: Animals; Cats; Cognition Disorders; Feline Acquired Immunodeficiency Syndrome; Immunodeficiency Virus, Feline; Isoleucine; Morpholines; Neuroprotective Agents; Receptor, Nerve Growth Factor

The p75 neurotrophin receptor (p75NTR) is involved in degenerative mechanisms related to Alzheimer's disease (AD). In addition, p75NTR levels are increased in AD and the receptor is expressed by neurons that are particularly vulnerable in the disease. Therefore, modulating p75NTR function may be a significant disease-modifying treatment approach. Prior studies indicated that the non-peptide, small molecule p75NTR ligands LM11A-31, and chemically unrelated LM11A-24, could block amyloid-β-induced deleterious signaling and neurodegeneration in vitro, and LM11A-31 was found to mitigate neuritic degeneration and behavioral deficits in a mouse model of AD. In this study, we determined whether these in vivo findings represent class effects of p75NTR ligands by examining LM11A-24 effects. In addition, the range of compound effects was further examined by evaluating tau pathology and neuroinflammation. Following oral administration, both ligands reached brain concentrations known to provide neuroprotection in vitro. Compound induction of p75NTR cleavage provided evidence for CNS target engagement. LM11A-31 and LM11A-24 reduced excessive phosphorylation of tau, and LM11A-31 also inhibited its aberrant folding. Both ligands decreased activation of microglia, while LM11A-31 attenuated reactive astrocytes. Along with decreased inflammatory responses, both ligands reduced cholinergic neurite degeneration. In addition to the amelioration of neuropathology in AD model mice, LM11A-31, but not LM11A-24, prevented impairments in water maze performance, while both ligands prevented deficits in fear conditioning. These findings support a role for p75NTR ligands in preventing fundamental tau-related pathologic mechanisms in AD, and further validate the development of these small molecules as a new class of therapeutic compounds.

Topics: Amyloid beta-Protein Precursor; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cerebral Cortex; Choline O-Acetyltransferase; Cholinergic Neurons; Cognition Disorders; Disease Models, Animal; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Humans; Isoleucine; Mice; Mice, Inbred C57BL; Mice, Transgenic; Morpholines; Mutation; Nerve Degeneration; Nerve Tissue Proteins; NIH 3T3 Cells; Phosphorylation; Protein Folding; Receptors, Nerve Growth Factor; tau Proteins

The p75 neurotrophin receptor (p75(NTR)) is associated with multiple mechanisms linked to Alzheimer's disease (AD); hence, modulating its function might confer therapeutic effects. In previous in vitro work, we developed small molecule p75(NTR) ligands that inhibited amyloid-β-induced degenerative signaling and prevented neurite degeneration. In the present study, a prototype p75(NTR) ligand, LM11A-31, was administered orally to the Thy-1 hAPP(Lond/Swe) (APP(L/S)) AD mouse model. LM11A-31 reached brain concentrations known to inhibit degenerative signaling without toxicity or induction of hyperalgesia. It prevented deficits in novel object recognition after 2.5 months and, in a separate cohort, deficits in Y-maze performance after 3 months of treatment. Stereology studies found that the number and size of basal forebrain cholinergic neurons, which are normal in APP(L/S) mice, were unaffected. Neuritic dystrophy, however, was readily apparent in the basal forebrain, hippocampus and cortex, and was significantly reduced by LM11A-31, with no effect on amyloid levels. These studies reveal that p75(NTR) is an important and tractable in vivo drug target for AD, with LM11A-31 representing a novel class of therapeutic candidates.

Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognition Disorders; Disease Models, Animal; Female; Isoleucine; Ligands; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Molecular Targeted Therapy; Morpholines; Nerve Degeneration; Neurites; Receptors, Nerve Growth Factor